Search Within

Lisa Bodei

  1. "Radiochemistry and Imaging Sciences Service"
Formats
  1. Book Section (8)
  2. Journal Article (7)
  3. Review (3)
  4. Book Whole (1)
  5. Editorial (1)
Groups
  1. Molecular Imaging and Therapy Service (20)
  2. Radiochemistry and Imaging Sciences Service (20)
  3. Radiology, Department of (20)
  4. Sloan Kettering Institute Postdocs (20)
  5. GSK Faculty (19)
  6. Center for Pancreatic Cancer Research (18)

More Groups

People
  1. Jason Lewis (18)
  2. Serge Lyashchenko (5)
  3. Heiko Schoder (4)
  4. Joseph O'Donoghue (4)
  5. Neeta Pandit-Taskar (4)
  6. Diane Reidy (3)

More People

Years
  1. 2024 (2)
  2. 2023 (9)
  3. 2022 (2)
  4. 2021 (2)
  5. 2020 (3)
  6. 2019 (2)
Publications
  1. Radiopharmaceutical Therapy (9)
  2. European Journal of Nuclear Medicine and Molecular Imaging (3)
  3. Journal of Nuclear Medicine (2)
  4. Clinical Cancer Research (1)
  5. Lancet Oncology (1)
  6. Nature Reviews Clinical Oncology (1)

More Publications

Publishers
  1. Springer (12)
  2. Nature Publishing Group (2)
  3. Society of Nuclear Medicine (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Case study #2: Disialoganglioside GD2 as a target for radiopharmaceutical therapy
    Book Section

    Cheung, N. K. V.; Kramer, K.; Modak, S.; Kushner, B. H.; Ahmed, M.; Santich, B.; Cheal, S.; Larson, S.
    In Bodei, L.; Lewis, J. S.; Zeglis, B. M. (Eds.) Radiopharmaceutical Therapy (2023)

    Fulltext@MSK | Save
  • Radiotheranostics in oncology: Current challenges and emerging opportunities
    Review

    Bodei, L.; Herrmann, K.; Schöder, H.; Scott, A. M.; Lewis, J. S.
    Nature Reviews Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer
    Journal Article

    Korsen, J. A.; Gutierrez, J. A.; Tully, K. M.; Carter, L. M.; Samuels, Z. V.; Khitrov, S.; Poirier, J. T.; Rudin, C. M.; Chen, Y.; Morris, M. J.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2022)

    Fulltext@MSK | Save
  • A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
    Journal Article

    Kalidindi, T. M.; Lee, S. G.; Jou, K.; Chakraborty, G.; Skafida, M.; Tagawa, S. T.; Bander, N. H.; Schoder, H.; Bodei, L.; Pandit-Taskar, N.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • γ-tocotrienol-loaded liposomes for radioprotection from hematopoietic side effects caused by radiotherapeutic drugs
    Journal Article

    Lee, S. G.; Kalidindi, T. M.; Lou, H.; Gangangari, K.; Punzalan, B.; Bitton, A.; Lee, C. J.; Vargas, H. A.; Park, S.; Bodei, L.; more...
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • The future of nuclear medicine, molecular imaging, and theranostics
    Editorial

    Weber, W. A.; Czernin, J.; Anderson, C. J.; Badawi, R. D.; Barthel, H.; Bengel, F.; Bodei, L.; Buvat, I.; DiCarli, M.; Graham, M. M.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Journal Article

    Krebs, S.; O'Donoghue, J. A.; Biegel, E.; Beattie, B. J.; Reidy, D.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; Pandit-Taskar, N.
    European Journal of Nuclear Medicine and Molecular Imaging (2020)

    Fulltext@MSK | Save
  • Radiopharmaceutical therapy in cancer: Clinical advances and challenges
    Review

    Sgouros, G.; Bodei, L.; McDevitt, M. R.; Nedrow, J. R.
    Nature Reviews Drug Discovery (2020)

    Fulltext@MSK | Save
  • Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-satoreotide tetraxetan
    Journal Article

    Reidy-Lagunes, D.; Pandit-Taskar, N.; O'Donoghue, J. A.; Krebs, S.; Staton, K. D.; Lyashchenko, S. K.; Lewis, J. S.; Raj, N.; Gönen, M.; Lohrmann, C.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Biodistribution and radiation dose estimates for (68)Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors
    Journal Article

    Krebs, S.; Pandit-Taskar, N.; Reidy, D.; Beattie, B. J.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; O'Donoghue, J. A.
    European Journal of Nuclear Medicine and Molecular Imaging (2019)

    Fulltext@MSK | Save